Studies have examined GLP-1 medicines after kidney transplantation, mostly in people with diabetes. A review of nine retrospective studies covered 338 recipients, including 240 who received a GLP-1 medicine [3]. The evidence does not establish how well the results apply to people using these medicines solely for weight loss.
What transplant studies found
In one retrospective study of 39 recipients, mean HbA1c fell from 8.4% to 7.4% and mean weight from 99.5 kg to 90.7 kg at the 13- to 18-month assessment [2]. The study found no significant change in graft function markers. Without a randomized comparison, it cannot establish how much of the change came from semaglutide or rule out rare harms.
The nine-study review found no clear change in average tacrolimus levels. Gastrointestinal symptoms were the most commonly reported side effects [3]. The group average does not predict what will happen to an individual patient’s medication levels.
How the transplant evidence differs from FLOW
The pooled semaglutide kidney analysis includes FLOW, a randomized trial in people with type 2 diabetes and chronic kidney disease. A separate FLOW analysis examined results across categories of kidney function and urine albumin [1]. Transplant studies address a different population and have less evidence about long-term graft outcomes.
The transplant evidence remains observational. Your transplant team can explain how those findings apply to your care.